Chronic hepatitis C with osteoporosis
Conditions
Interventions
Sponsors
Department of Hepatology, Osaka City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The following chronic hepatitis C patients with Genotype 1 and high viral lord were eligible to enter the trial Osteoporosis HCV-RNA>=5.0 LogIU/mL WBC counts>=3,000/microL Neutrophil counts>=1,500/microL Hemoglobin concentration>=12g/dL Platelet counts>=90,000/microL the presense of liver biopsy is not asked the presense of the IFN treatment history is not asked patients who provided written informed consent to participate the study prior to enrollment
Exclusion criteria
Exclusion criteria: The following patients were excluded women of childbearing potential and pregnancy, lactating women allergic to ribavirin or other nucleoside analoges an uncontrollable heart trouble( myocardial infarction, heart failure, or arrhythmia) hemoglobibopathy ( thalassemia, sickle cell disease) severe renal disease or Ccr<50mL/min severe depression or psychosomatic disorders severe liver disease autoimmune hepatitis or HBV drug allegy against interferon allergic to vaccine or biological preperations concomitant herbal medication of Sho-saiko-to history of interstitial pneumonia patients who take active vitamin D3 other than Eldecalcitol other conditions considerd inappropriate by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sustained Virological Response ( SVR ) | — |
Secondary
| Measure | Time frame |
|---|---|
| ALT normalization Safety | — |
Countries
Japan
Outcome results
None listed